'Placebo' presentation slideshows

Introduction

Introduction. Clare Kahn, Ph.D. Vice President, US Regulatory Affairs Cardiovascular, Urogenital & Metabolic Products, GlaxoSmithKline. Carvedilol. Pharmacological Properties Nonselective b -adrenergic receptor antagonist ? 1 -adrenergic receptor antagonist. Mild. Moderate. Severe.

1.77k views • 130 slides

Vaccines and Related Biological Products Advisory Committee Meeting Prevnar 13: Pneumococcal 13-valent Conjugate Vacc

Vaccines and Related Biological Products Advisory Committee Meeting Prevnar 13: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM 197 Protein] Applicant: Wyeth Pharmaceuticals Inc. Tina Khoie, M.D., M.P.H FDA/CBER/OVRR/DVRPA November 18, 2009. Presentation Outline.

1.39k views • 97 slides

927 views • 68 slides

Perinatal Transmission and HIV: Two Realities

801 views • 56 slides

Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndr

Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome. Canadian Cardiovascular Society Antiplatelet Guidelines.

752 views • 49 slides

Moving from Problems

574 views • 47 slides

Management of Behavioral and Psychological Symptoms in People with Dementia Living in Care Homes: A UK Perspective

673 views • 44 slides

Food Allergy Update

2.12k views • 39 slides

575 views • 39 slides

Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus and Chronic Stable Angina Results from the TERISA Ran

Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus and Chronic Stable Angina Results from the TERISA Randomized Clinical Trial.

644 views • 36 slides

Selection of D in Clinical Trials of Antimicrobial Therapy - Acute Exacerbation of Chronic Bronchitis

Selection of D in Clinical Trials of Antimicrobial Therapy - Acute Exacerbation of Chronic Bronchitis. Susan D. Thompson, M.D. February 19, 2002. Acute Exacerbation of Chronic Brochitis (AECB) - Outline. Definition and scope of the problem Selection of D for AECB trials

614 views • 35 slides

The future of pharmacological treatment.

Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. The future of pharmacological treatment. What substances and when?. What Nicotine Alcohol Cannabis Opiates Stimulants Cocaine Methamphetamine Amphetamine Ecstasy

504 views • 35 slides

The Placebo Effect

3.16k views • 28 slides

Artesunate Rectal Capsules

Artesunate Rectal Capsules. For the initial management of acute malaria in patients who cannot take medication by mouth and for whom parenteral treatment is not available

634 views • 15 slides

Sofosbuvir-Velpatasvir- Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1

277 views • 11 slides

PRESENTAZIONE E DISCUSSIONE DEGLI ELABORATI DEI GRUPPI DI LAVORO

213 views • 9 slides

Behandeling van sinustrombose

Behandeling van sinustrombose. plaatje. P : patient met cerebrale sinustrombose I : antistollings therapie C : geen antistolling / placebo O : functionele outcome / mortaliteit. Anticoagulation for cerebral sinus thrombosis Stam/de Bruijn/DeVeber Cochrane Library.

594 views • 8 slides

Mother and Child Health: Research Methods

Mother and Child Health: Research Methods. G.J.Ebrahim Editor Journal of Tropical Pediatrics, Oxford University Press . Basic Design of Clinical Trials. Cured. Same. Treatment. Sample. Randomise. Blinding. Placebo. Cured. Same. Subjects. Blocking. Variations in Basic Design -1.

186 views • 8 slides

Atorvastatin in Type 2 diabetics on dialysis: 4D Study

Atorvastatin in Type 2 diabetics on dialysis: 4D Study. 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF; 45% PAD Baseline lipids: LDL-C 3.2 mmol /L;TG 3.0 mmol/L Atorva 20mg vs Pbo x 4 yrs; ? LDL-C: 1 mmol/L. 60.

345 views • 6 slides

Kaplan-Meier Curve of Time to Primary End Point

0. 6. 12. 24. 30. 36. 18. Kaplan-Meier Curve of Time to Primary End Point. Pioglitazone (514 events) Placebo (572 events). Proportion of Events (%). HR = 0.90 (95% CI 0.80-1.02) p = 0.095. Time from Randomization (months). No. at Risk. Pioglitazone Placebo. 2488 2530. 2373 2413.

292 views • 4 slides